FeesSafety
Pluang+

JPMorgan Income ETF (JPIE) rated Buy for its strong income and controlled risk amid high inflation and rates.

Market News
08 Nov 2026, 20:17 WIB
Seeking Alpha
View Source
Bullish
JPMorgan Income ETF (JPIE) rated Buy for its strong income and controlled risk amid high inflation and rates.

The JPMorgan Income ETF (JPIE) is recommended as a Buy due to its focus on securitized assets, which currently offer better premiums than corporate bonds. The ETF is expected to provide high income with a controlled risk profile, making it a solid choice for bond allocation in a market environment of persistent inflation and high interest rates. The author believes active bond management, as employed by JPIE, will outperform typical aggregate and high yield bond alternatives post-midterm elections. This view is based on the current economic context of high federal deficits and abundant Treasury supply.

Regarding the JPMorgan Income ETF (JPIE), here is Pluang's market snapshot as of Nov 08, 2026 22:02 WIB: Among 150 priced US stocks tradable on Pluang, 76 rose and 74 fell. Notable movers include PLUG (Plug Power Inc) at USD 1.45 with a 7.41% increase and a typical hold time of 43 days, FIRY (Firy Inc.) at USD 11.48 up 6.79%, and XPEV (Xpeng Inc - ADR) at USD 10.24 rising 6.67% with a typical hold time of 83 days. The most notable figure is the Pluang order activity for PLUG, showing 97% Sell and 3% Buy.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
3 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
3 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
3 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
3 hours ago
Petrobras starts using Cardano blockchain to track sustainable aviation fuel claims.

Petrobras starts using Cardano blockchain to track sustainable aviation fuel claims.

Petrobras has begun using the Cardano blockchain to track claims related to sustainable aviation fuel (SAF). Digital tokens on Cardano represent the environmental attributes of the fuel and remain linked through its production, shipment, and use. Thi...

Protocol Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App